Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Current Investments: 2013-2024

Historic Cash & Current Investments for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $149.8 million.

  • ImmunityBio's Cash & Current Investments rose 97.76% to $257.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $622.9 million, marking a year-over-year decrease of 20.68%. This contributed to the annual value of $149.8 million for FY2024, which is 43.78% down from last year.
  • Per ImmunityBio's latest filing, its Cash & Current Investments stood at $149.8 million for FY2024, which was down 43.78% from $266.5 million recorded in FY2023.
  • ImmunityBio's 5-year Cash & Current Investments high stood at $317.1 million for FY2021, and its period low was $96.1 million during FY2020.
  • Over the past 3 years, ImmunityBio's median Cash & Current Investments value was $149.8 million (recorded in 2024), while the average stood at $174.5 million.
  • In the last 5 years, ImmunityBio's Cash & Current Investments surged by 230.12% in 2021 and then tumbled by 66.20% in 2022.
  • Over the past 5 years, ImmunityBio's Cash & Current Investments (Yearly) stood at $96.1 million in 2020, then spiked by 230.12% to $317.1 million in 2021, then tumbled by 66.20% to $107.2 million in 2022, then soared by 148.60% to $266.5 million in 2023, then plummeted by 43.78% to $149.8 million in 2024.